The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study

Inclusion criteria

• Age>18 years old, gender unlimited;
• According to the Diagnosis and Treatment Guidelines for Primary Lung Cancer (2018 Edition), NSCLC was diagnosed by pathological histology;
• TNM staging is III - IV;
• Failure of second-line treatment according to the CSCO guidelines;
• ECOG PS score ≤ 2 points;
• Estimated survival time>3 months;
• Sign informed consent form

Exclusion criteria

• Individuals who have previously received interventional therapy (iodine particle implantation, ablation, BACE treatment), or have received PD-L1 inhibitor immunotherapy during the first or second line standard treatment period of the patient;
• Patients with other malignant tumors that have not been cured;
• White blood cells<3 × 109/L, absolute value of neutrophils<1.5 × 109/L, neutrophil/lymphocyte ratio ≥ 3, platelet count<50 × 109/L, hemoglobin concentration<90 g/L;
• Liver and kidney dysfunction (creatinine>176.8) μ Mol/L; Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)>twice the normal upper limit;
• Central squamous cell carcinoma with cavity features;
• Incorrectable coagulation dysfunction or concomitant active massive hemoptysis;
• Patients with concurrent active infections who require antibiotic treatment;
• Uncontrollable hypertension, diabetes, and cardiovascular diseases with obvious symptoms;
• Contrast agent allergy;
• Women with concurrent pregnancy or lactation